Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	8/8/2007 5:19:36 PM
	Read Replies (1) of 3044

NEW YORK (AP) -- A Cowen and Co. analyst initiated or revised coverage on several biotechnology stocks Wednesday.... ....McMinn maintained a "Neutral" rating on Cambridge, Mass.-based Millennium Pharmaceuticals Inc. She said the company's multiple myeloma treatment Velcade has become a standard treatment, but its future is uncertain as new competition enters the market, including Celgene Inc's cancer drug Revlimid. Two things need to happen to bring back investor interest to the stock, she said. "First, the company must post a few more quarters of solid results in the face of Revlimid competition. Second, there must be visibility on something - either a pipeline project or the use of Velcade in a new indication -- that is capable of driving top-line growth ahead of the Street's expectations," she said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next